In cognitively normal older adults at risk for Alzheimer’s dementia, physical inactivity was associated with faster tau protein buildup and cognitive decline.

The latest large language model from OpenAI offers safety gains, persistent risks and the illusion of understanding.

The future of HIV research — and of the USA’s scientific leadership — depends on bold, sustained action in defense of discovery, investment, and innovation.

After years of stigma, psychedelic compounds are edging closer to regulatory approval, with pivotal trials in tough-to-treat depression and anxiety underway.

As presented at the American Heart Association Conference 2025, patients with chest pain and without obstructive coronary artery disease benefit from treatment informed by cardiovascular magnetic resonance.

As presented at AHA Scientific Sessions 2025, in a trial emulation analysis including benchmarking to data from randomized clinical trials, treatment with semaglutide and tirzepatide showed similar levels of benefit on cardiovascular outcomes in individuals at elevated cardiovascular risk with obesity and diabetes.

Elebsiran plus PEG-IFNα improved hepatitis B surface antigen (HBsAg) loss rates compared with PEG-IFNα alone in patients with chronic hepatitis B virus infection. Furthermore, prior response to the BRII-179 vaccine was associated with higher HBsAg clearance, suggesting its potential as a predictive tool for identifying patients more likely to benefit from therapies.

In a meta-analysis of 48 randomized trials of chronic kidney disease progression, reduction in the 6-month urinary albumin:creatinine ratio was associated with lower hazard ratios of established kidney disease endpoints, supporting the use of albuminuria change as a surrogate endpoint in clinical trials for chronic kidney disease.

Pretrained using 335,645 whole-slide images, a foundation model is developed to provide representations for slide- and patient-level tasks. It is capable of performing clinical tasks and generating reports even in data-scarce scenarios, such as rare cancer diagnosis and survival prediction, without requiring further fine-tuning.

In this follow-up study presenting results at 96 weeks, cabotegravir and rilpivirine long-acting therapy remained noninferior to oral therapy, had acceptable safety and tolerability profiles, and resulted in durable virologic suppression, further supporting its consideration for African treatment programs.

Shorena Janelidze recalls the discovery of phosphorylated tau, from early lab work to clinical implementation.

Stem cell science is at a pivotal moment, and decades of research have the potential to transform human health.

The first month-by-month analysis of malnutrition in children of preschool age in Gaza reveals the acute impact of aid restrictions and conflict — with the most recent estimates showing more than 50,000 children severely malnourished.

The future of HIV research — and of the USA’s scientific leadership — depends on bold, sustained action in defense of discovery, investment, and innovation.